Background
==========

COPD from pharmacoeconomic perspective
--------------------------------------

Chronic obstructive pulmonary disease (COPD) is a common chronic condition in people over the age of 50 years. Rapid population aging in developed countries is considered to be the main reason for higher prevalence of chronic diseases, including COPD. These changes will require some specific actions undertaken by health system decision-makers \[[@b1-medscimonit-23-2850]\].

According to WHO estimates, there are more than 65 million people worldwide suffering from COPD. This is also an important health problem in Poland. It is estimated that 10.1--10.2% of Poles have COPD \[[@b2-medscimonit-23-2850],[@b3-medscimonit-23-2850]\]. This is equivalent to approximately 2 million people, out of whom, 20% have an advanced stage of the disease (stage III and IV according to GOLD classification of obturation) \[[@b4-medscimonit-23-2850]\].

COPD imposes a heavy economic burden on health systems. Expenditures are approximately EUR 38.6 billion a year, of which 40--75% is spent on treatment of exacerbations requiring hospitalization \[[@b5-medscimonit-23-2850]--[@b9-medscimonit-23-2850]\]. Therefore, preventing exacerbations is the biggest medical and economic challenge. Similarly, in Poland, unstable disease with frequent exacerbations is related to expenditures higher by PLN 1600/year (≈EUR 366.60) than in patients with stable disease \[[@b10-medscimonit-23-2850]\]. In-hospital treatment of an exacerbation is up to 10 times more expensive than outpatient treatment \[[@b11-medscimonit-23-2850]\].

Thus, to achieve more effective management of the disease, particularly in advanced COPD, an innovative type of care was proposed. The Integrated Care Model (ICM) is an intervention developed in Gdansk (Pomeranian Province, Poland). The main goal of ICM was to decrease the number of exacerbations and stabilize patient condition, thereby limiting National Health Fund (NHF) expenditures.

The intervention -- Integrated Care Model (ICM)
-----------------------------------------------

ICM includes general and specialist care combined with home support for patients, and intensive education of patients and their relatives.

All actions are synchronized by the program coordinator, who is also responsible for supervising the proper use of drugs by the patients and coordinating their visits to GPs and pulmonologists ([Figure 1](#f1-medscimonit-23-2850){ref-type="fig"}).

As shown in [Figure 1](#f1-medscimonit-23-2850){ref-type="fig"}, the coordinator is responsible for providing ongoing support to the patients. This is a non-medical staff member who has completed a specialist course in a coordination of treatment of chronically ill patients, organized by a hospice foundation, who has participated in educational training on COPD, according to the educational program developed by one of the present co-authors -- Iwona Damps-Konstanska, MD, PhD.

The coordinator provides patient support by:

1.  -- preparing the schedule of medical and non-medical activities for ICM patients;

2.  -- communicating with all ICM members;

3.  -- contacting patients by phone once every 2 weeks to assess their general health condition, if they are medication-compliant, and if they require attention of medical or non-medical staff;

4.  -- coordinating education of patients and their families by organizing trainings.

Within ICM there are 2 multidisciplinary teams working in close collaboration to assure optimal patient-oriented care.

1.  The ICM medical team consists of:

    1.  -- pulmonologists;

    2.  -- medical doctors in other specializations, such as endocrinologists, cardiologists, or gastroenterologists (but only within standard care cooperation);

    3.  -- GPs;

    4.  -- nurses.

2.  The ICM non- medical team consists of:

    1.  -- patient assistants;

    2.  -- dietitians;

    3.  -- psychologists;

    4.  -- physiotherapists;

    5.  -- social workers;

    6.  -- priests.

All team members are cooperating not only with each other but also with patients and their relatives. The innovative element is to integrate the activities of medical specialists and non-medical staff and to provide home support for patients with poor self-management and problems with compliance with medical recommendations.

Aim
---

The aim of this study was to estimate COPD costs and to analyze the impact of introducing integrated care (IC) on the public budget.

Secondary endpoints included the evaluation of:

1.  -- direct medical costs for patients included and not included in ICM;

2.  -- changes in costs before and after including patients in ICM;

3.  -- changes in the frequency of using specific types of medical services.

Material and Methods
====================

Study population
----------------

The study included 175 patients diagnosed with advanced COPD. The mean age of the study group was 71 years old (46--88 years) and 65% were men. The baseline characteristics are presented in [Table 1](#t1-medscimonit-23-2850){ref-type="table"}.

Cost analysis
-------------

This was a "before-after" study. The first period, called "intro-6m" (meaning 6 months before introducing ICM), included 6 months of standard treatment received by all the patients. After 6 months, the study group was divided into 2 subgroups:

1.  -- subgroup 1 called "ICM-no" continued standard type of care (n=131);

2.  -- subgroup 2 called "ICM-yes" received integrated care (n=44).

The observation lasted for another 6 months after dividing patients into subgroups (the period called "intro+6m"). Based on prior studies on IC, the study included patients who fulfilled the specified criteria ([Figure 2](#f2-medscimonit-23-2850){ref-type="fig"}).

Finally, the cost analysis included 154 patients. The dropouts from the study were a result of: death during the observation period (n=16), lack of COPD-related costs (n=2), and exacerbation costs (n=87). The cost analysis was divided into 3 stages. The types of costs analyzed in the study are presented in [Table 2](#t2-medscimonit-23-2850){ref-type="table"}.

Selection of DRG (*Diagnosis-Related Groups*) codes to describe the list of services included in the particular stages of the analysis was done on the basis of the clinical expertise of the 2 authors independently. The cost data were provided by the NHF and covered the time period from September 2012 to the end of June 2014.

The analysis included the following steps:

1.  Calculating costs of standard care for all the patients included in the study;

2.  Calculating costs of IC for patients fulfilling the specified criteria ([Figure 2](#f2-medscimonit-23-2850){ref-type="fig"});

3.  Estimating changes in values of costs of all types ([Table 2](#t2-medscimonit-23-2850){ref-type="table"});

4.  Assessing changes in types of medical procedures after replacing SC with IC;

5.  Assessing changes in types of medical services providers engaged into taking care of patients after replacing SC with IC.

Statistical analysis
--------------------

All calculations were carried out using Microsoft Excel spreadsheets and the STATISTICA, StatSoft Inc. version 8.0. statistical package. The normality of the variables distribution and variance equality of a studied feature in groups were tested using both an appropriate Shapiro-Wilk's test and a variance equality test. When assessing changes in time, the Wilcoxon's matched-pairs signed-rank test was used. In all the calculations, the statistical significance level was set to p\<0.05.

Results
=======

First, the standard care costs for 6 months were evaluated for all the patients included in the cost analysis (n=154). The average half-year cost was PLN 3870.26 (≈EUR 886.78), whereas the maximal cost exceeded PLN 4500 (≈ EUR 10310.69) ([Table 3](#t3-medscimonit-23-2850){ref-type="table"}).

The next step was to assess the changes in values of 3 costs types after implementation of ICM to the group of patients who fulfilled the criteria and were included in ICM. The summary data on cost changes is presented in [Table 4](#t4-medscimonit-23-2850){ref-type="table"}.

General costs
-------------

General costs were analyzed in 2 consecutive periods: before and after including patients into ICM. We found that general direct medical costs decreased. Both average and median values were reduced to PLN 2050.50 (≈EUR 469.82) and PLN 1319.93 (≈EUR 302.43), respectively, after 6 months of ICM. However, the Wilcoxon's signed-rank test showed no statistical significance of the differences in the distribution of parameters (p=0.079114).

COPD costs
----------

The costs related to COPD and other respiratory system diseases decreased significantly (Wilcoxon's Matched-Pairs Signed-Rank p=0.012492). Both average and median values were reduced to PLN 1450.12 (≈EUR 332.26) and PLN 2010.60 (≈EUR 460.68), respectively, after 6 months of ICM.

Exacerbation costs
------------------

The last stage of cost analysis was to assess exacerbation-related costs. These costs also decreased significantly (Wilcoxon's matched-pairs signed-rank p=0.017023). Both average and median costs were lowered to PLN 1708.44 (≈EUR 391.45) and PLN 1872.00 (≈EUR 428.92), respectively, after 6 months of ICM. Median costs after introducing ICM were PLN 0 (EUR 0). Eighteen (approximately 70%) of the 26 patients included in this stage of the cost analysis had no exacerbation-related costs during 6 months of ICM.

Changes in the number of medical procedures provided for patients
-----------------------------------------------------------------

After including patients in ICM, the number of medical procedures used in treating their health condition changed. There was a decrease in the number of medical services provided in most of the cases, except from gastrointestinal diseases ([Figure 3](#f3-medscimonit-23-2850){ref-type="fig"}).

A similar comparison was done for the type of medical services provider. The number of services provided by GPs increased along with a decrease in the number of hospitalizations and services provided by emergency departments and paramedic teams ([Figure 4](#f4-medscimonit-23-2850){ref-type="fig"}).

Discussion
==========

According to numerous studies, IC is a relevant and essential medical technology in the management of advanced COPD \[[@b12-medscimonit-23-2850]--[@b14-medscimonit-23-2850]\]. At the present time, it seems reasonable to determine the economic effectiveness of this technology with the use of pharmacoeconomic tools. In Poland, the role of pharmacoeconomic analyses is systematically growing and they are currently used for assessing all new and expensive procedures. They are particularly important in selecting optimal medical technologies for managing chronic diseases, including COPD, as these conditions are related to particularly high costs \[[@b11-medscimonit-23-2850]--[@b17-medscimonit-23-2850]\].

Back in 2007, in Poland, it was found that the average direct medical costs of COPD were PLN 4027 per 1 year (≈EUR 922.69) \[[@b10-medscimonit-23-2850]\]. In the present study, after 8 years, the average costs were PLN 3191.43 per 6 months (≈EUR 731.24) when standard care was used. Nevertheless, in our study, we decided to analyze not only COPD-related costs, but also costs of all procedures provided for patients, as it has already been proven that assessing only COPD costs is not sufficient for the meticulous calculation of actual economic burden, mainly due to the presence of multiple co-morbidities \[[@b10-medscimonit-23-2850],[@b18-medscimonit-23-2850],[@b19-medscimonit-23-2850]\].

Furthermore, earlier studies showed that severity of COPD is related to cost of care \[[@b8-medscimonit-23-2850]\], especially costs due to frequent hospitalizations \[[@b20-medscimonit-23-2850]\]. This is one reason why ICM should be indicated for patients with advanced COPD with severe and very severe obstruction of the airways.

The cost analysis proved that patients fulfilling the criteria for participation in ICM were in a worse health status, which was confirmed by higher costs of care in the primary assessment. By comparing costs calculated for all patients (n=154) and for the ICM-yes group in the period before introducing ICM, we noticed that the costs were lower: 31% lower for general costs, 49% lower for COPD costs, and 36% lower for exacerbation costs. This confirms that the correct inclusion criteria were planned for the study, as the intention of the authors was to make ICM available for the patients in more severe condition.

In numerous "before-after" studies, authors found that implementing IC results in savings. In the Steuten et al. study, the decrease in direct medical costs was EUR 42 \[[@b21-medscimonit-23-2850]\]. In our study, the difference between average costs was even greater (PLN 2050.48 ≈EUR 489). Even after taking into account that ICM requires additional financing (PLN 915.18/6 months/1patient ≈EUR 209.69), in 1 year it is still possible to save EUR 543 per patient. This shows that the construction of the model proposed in Gdansk is well adjusted to the needs of COPD patients and might be an important tool for managing COPD and limiting health system expenditures. ICM is a complex intervention that includes medical and non-medical staff support provided at patients' homes, cooperation of specialist care with GPs, and supervision of adherence to medical recommendations (for a comparison of elements available for patients, see [Table 5](#t5-medscimonit-23-2850){ref-type="table"}). A similar observation concerning the positive impact of integrated care on costs was found in 2014 by van Boven et al. \[[@b22-medscimonit-23-2850]\], who reported savings of EUR 227 per patient.

It is worth noting, though, that no statistically significant changes were found in general costs. However, after entering ICM, patients visited specialists such as dermatologists or dentists more often, which influenced the general costs. We perceive this phenomenon as positive, and it might indicate that health status improved and patients were able to use medical services that were out of reach for them before entering ICM because of poor health.

The statistically significant decrease in the COPD costs indicates that fewer procedures were provided after including patients in ICM. We believe that many health needs were satisfied by ICM and no additional procedures were necessary. Therefore, ICM seems to be appropriate for patients with advanced COPD.

Numerous have studies concentrated on the significance of preventing exacerbations that require hospitalizations \[[@b23-medscimonit-23-2850]\]. This is particularly important because an exacerbation requiring hospitalization usually results in significant deterioration in health status \[[@b6-medscimonit-23-2850]\].

The decrease noticed in the exacerbation-related costs may also be considered as a decreasing number of exacerbations. Before ICM was implemented, approximately 47.7% of patients required medical services typical for exacerbations ([Table 3](#t3-medscimonit-23-2850){ref-type="table"}). In the group of patients meeting the criteria of inclusion to ICM, the prevalence was even higher; exacerbation-related procedures were provided for 73% of patients. After 6 month of ICM in the group "ICM-yes" only 31% of patients required procedures provided for exacerbations. A similar observation was recently made by Titova et al., who noticed a difference in the number of hospitalizations between patients receiving IC and those receiving regular care (12.6% reduction in the first year and 46.5% reduction during the second year of follow-up, in comparison to 8.3% increase in the first year and no change during the second year of follow-up) \[[@b24-medscimonit-23-2850]\].

These results seem to be encouraging. Furthermore, it is worth noting that ICM seems to be more effective than many IC models described by other authors \[[@b22-medscimonit-23-2850],[@b25-medscimonit-23-2850]\]. For example, in a recent study by Hernandez et al., there was no reduction in the number of hospital admission found in IC in comparison with SC for stable patients \[[@b26-medscimonit-23-2850]\]. Some authors found no economic efficacy of integrated care \[[@b27-medscimonit-23-2850]\]. In a recently published cluster study on cost-effectiveness of IC in COPD, no economic benefit was found \[[@b28-medscimonit-23-2850]\]. [Table 5](#t5-medscimonit-23-2850){ref-type="table"} shows differences and similarities between studies dealing with IC in COPD.

As contemporary knowledge of the economic effectiveness of integrated care is still not clear, the present study, conducted in Gdansk, proves ICM is an effective tool. We hope our results will be important in the worldwide discussion regarding designing effective models of care for patients and the healthcare system finances.

Conclusions
===========

We found that ICM is a beneficial intervention for patients and the public payer. After including patients in ICM, their demand for medical services changed. The patients were rarely hospitalized and used services provided by outpatient clinics more often. Fewer procedures were continued in treating respiratory system disorders, which might indicate an improvement in the health of ICM patients.

The costs of care provided for advanced COPD patients are high, which indicates a need to evaluate traditionally used medical services and to looking for more effective ones, both from the medical and economic point of view. It seems that ICM meets these criteria, as medical costs of all analyzed types decreased when standard care was replaced by IC. Statistically significant changes were observed in costs related to COPD and exacerbations.

The obtained results show that ICM can be an effective tool to manage advanced COPD, because it reduces the number of exacerbations and therefore limits public expenditures.

Implications
------------

This article is particularly relevant in countries where integrated care is still being implemented \[[@b29-medscimonit-23-2850]\]. For specialists already using integrated care, this study confirms that IC can benefit COPD patients and the healthcare system. In countries that are still adjusting their health system to current and future challenges (e.g., demographic changes), the results obtained in Gdansk can be a guide to choosing a beneficial model of care. After an analysis of the literature on IC, it is clear that scientific discussion on the effectiveness of this type of care is still open.

Limitations
-----------

This study has some limitations. The number of patients included in ICM was small because ICM still has no stable source of financing and is not financed from the budget of the NHF. Another limitation was using the public payer perspective in the cost analysis instead of the societal one, which is considered to be the most extensive and complete. In Poland, conducting cost analysis from the societal perspective is very difficult due to a limited access to data that is highly dispersed and collected on a fragmentary basis by various institutions. Due to using the public payer perspective, it was impossible to assess indirect costs.

Supplementary Tables
====================

###### 

List of diseases and related health problems requiring procedures qualified to costs of COPD and other diseases of respiratory system

  ICD-10 code   Name                                                                                   Reason for inclusion
  ------------- -------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------
  I26           Pulmonary embolism                                                                     Frequent cause of death
  I26.9         Pulmonary embolism without mention of acute cor pulmonale                              Frequent cause of death
  I27           Other pulmonary heart diseases                                                         Frequent cause of death
  I27.8         Other specified pulmonary heart diseases                                               Frequent cause of death
  I27.9         Pulmonary heart disease, unspecified                                                   Frequent cause of death
  J00           Acute nasopharyngitis                                                                  Frequent occurrence in patients with COPD
  J02           Acute pharyngitis                                                                      Frequent occurrence in patients with COPD
  J03           Acute tonsillitis                                                                      Frequent occurrence in patients with COPD
  J04           Acute laryngitis and tracheitis                                                        Frequent occurrence in patients with COPD
  J06           Acute upper respiratory infections of multiple and unspecified sites                   Frequent occurrence in patients with COPD
  J13           Pneumonia due to Streptococcus pneumoniae                                              Frequent occurrence in patients with COPD
  J15           Bacterial pneumonia, not elsewhere classified                                          Frequent occurrence in patients with COPD
  J15.1         Pneumonia due to Pseudomonas                                                           Frequent occurrence in patients with COPD
  J15.4         Pneumonia due to other streptococci                                                    Frequent occurrence in patients with COPD
  J15.5         Pneumonia due to Escherichia coli                                                      Frequent occurrence in patients with COPD
  J15.6         Pneumonia due to other aerobic Gram-negative bacteria                                  Frequent occurrence in patients with COPD
  J15.8         Other bacterial pneumonia                                                              Frequent occurrence in patients with COPD
  J15.9         Bacterial pneumonia, unspecified                                                       Frequent occurrence in patients with COPD
  J16           Pneumonia due to other infectious organisms, not elsewhere classified                  Frequent occurrence in patients with COPD
  J16.8         Pneumonia due to other specified infectious organisms                                  Frequent occurrence in patients with COPD
  J18           Pneumonia, organism unspecified                                                        Frequent occurrence in patients with COPD
  J18.9         Pneumonia, unspecified                                                                 Frequent occurrence in patients with COPD
  J20           Acute bronchitis                                                                       Frequent occurrence in patients with COPD
  J20.9         Acute bronchitis, unspecified                                                          Frequent occurrence in patients with COPD
  J21           Acute bronchiolitis                                                                    Frequent occurrence in patients with COPD
  J22           Unspecified acute lower respiratory infection                                          Frequent occurrence in patients with COPD
  J31           Chronic rhinitis, nasopharyngitis and pharyngitis                                      In connection with the use of inhalers
  J32.4         Chronic pansinusitis                                                                   Frequent occurrence in patients with COPD
  J37           Chronic laryngitis and laryngotracheitis                                               Frequent occurrence in patients with COPD
  J39           Other diseases of upper respiratory tract                                              Frequent occurrence in patients with COPD
  J39.2         Other diseases of pharynx                                                              Frequent occurrence in patients with COPD
  J40           Bronchitis, not specified as acute or chronic                                          Frequent occurrence in patients with COPD
  J41           Simple and mucopurulent chronic bronchitis                                             Frequent occurrence in patients with COPD
  J41.0         Simple chronic bronchitis                                                              Frequent occurrence in patients with COPD
  J41.8         Mixed simple and mucopurulent chronic bronchitis                                       Frequent occurrence in patients with COPD
  J42           Unspecified chronic bronchitis                                                         Frequent occurrence in patients with COPD
  J43           Emphysema                                                                              Frequent occurrence in patients with COPD
  J43.8         Other emphysem                                                                         Frequent occurrence in patients with COPD
  J43.9         Emphysema, unspecified                                                                 Frequent occurrence in patients with COPD
  J44           Other chronic obstructive pulmonary disease                                            Code assigned for COPD
  J44.0         Chronic obstructive pulmonary disease with acute lower respiratory infection           Frequent occurrence in patients with COPD
  J44.1         Chronic obstructive pulmonary disease with acute exacerbation, unspecified             Frequent occurrence in patients with COPD
  J44.8         Other specified chronic obstructive pulmonary disease                                  Frequent occurrence in patients with COPD
  J44.9         Chronic obstructive pulmonary disease, unspecified                                     Frequent occurrence in patients with COPD
  J45           Asthma                                                                                 Difficult in differentiation with COPD (especially at the level of care primary care)
  J45.0         Predominantly allergic asthma                                                          Difficult in differentiation with COPD (especially at the level of care primary care)
  J45.1         Nonallergic asthma                                                                     Difficult in differentiation with COPD (especially at the level of care primary care)
  J45.8         Mixed asthma                                                                           Difficult in differentiation with COPD (especially at the level of care primary care)
  J45.9         Asthma, unspecified                                                                    Difficult in differentiation with COPD (especially at the level of care primary care)
  J46           Status asthmaticus                                                                     Difficult in differentiation with COPD (especially at the level of care primary care)
  J47           Bronchiectasis                                                                         Difficult in differentiation with COPD (especially at the level of care primary care)
  J84           Other interstitial pulmonary diseases                                                  Frequent occurrence in patients with COPD
  J84.1         Other interstitial pulmonary diseases with fibrosis                                    Frequent occurrence in patients with COPD
  J84.8         Other specified interstitial pulmonary diseases                                        Frequent occurrence in patients with COPD
  J84.9         Interstitial pulmonary disease, unspecified                                            Frequent occurrence in patients with COPD
  J85.1         Abscess of lung with pneumonia                                                         Frequent occurrence in patients with COPD
  J93           Pneumothorax                                                                           Frequent occurrence in patients with COPD
  J93.1         Spontaneous tension pneumothorax                                                       Frequent occurrence in patients with COPD
  J93.8         Other pneumothorax                                                                     Frequent occurrence in patients with COPD
  J94           Other pleural conditions                                                               Frequent occurrence in patients with COPD
  J96           Respiratory failure, not elsewhere classified                                          Frequent occurrence in patients with COPD
  J96.0         Acute respiratory failure                                                              Frequent occurrence in patients with COPD
  J96.1         Chronic respiratory failure                                                            Frequent occurrence in patients with COPD
  J96.9         Respiratory failure, unspecified                                                       Frequent occurrence in patients with COPD
  J98           Other respiratory disorder                                                             Frequent occurrence in patients with COPD
  J98.4         Other disorders of lung                                                                Frequent occurrence in patients with COPD
  J98.8         Other specified respiratory disorders                                                  Frequent occurrence in patients with COPD
  J98.9         Respiratory disorder, unspecified                                                      Frequent occurrence in patients with COPD
  J99           Respiratory disorders in diseases classified elsewhere                                 Frequent occurrence in patients with COPD
  K13           Other diseases of lip and oral mucosa                                                  In connection with the use of inhalers
  L25           Unspecified contact dermatitis                                                         In connection with the use of inhalers
  R04           Haemorrhage from respiratory passages                                                  Frequent occurrence in patients with COPD
  R04.2         Haemoptysis                                                                            Frequent occurrence in patients with COPD
  R05           Cough                                                                                  Frequent occurrence in patients with COPD
  R06           Abnormalities of breathing                                                             Frequent occurrence in patients with COPD
  R06.0         Dyspnoea                                                                               Frequent occurrence in patients with COPD
  R07           Pain in throat and chest                                                               Frequent occurrence in patients with COPD
  R07.1         Chest pain on breathing                                                                Frequent occurrence in patients with COPD
  R07.3         Other chest pain                                                                       Frequent occurrence in patients with COPD
  R07.4         Chest pain, unspecified                                                                Frequent occurrence in patients with COPD
  R09.8         Other specified symptoms and signs involving the circulatory and respiratory systems   Frequent occurrence in patients with COPD
  R91           Abnormal findings on diagnostic imaging of lung                                        Frequent occurrence in patients with COPD

###### 

The list of diseases and related health problems requiring procedures qualified to costs of exacerbations of COPD

  ICD-10 code   Name                                                                           Reason for inclusion
  ------------- ------------------------------------------------------------------------------ ------------------------------------------
  J44.1         Chronic obstructive pulmonary disease with acute exacerbation, unspecified     Assigned for exacerbation of COPD
  J44.0         Chronic obstructive pulmonary disease with acute lower respiratory infection   Frequently used for exacerbation of COPD
  J22           Unspecified acute lower respiratory infection                                  Frequently used for exacerbation of COPD
  J96           Respiratory failure, not elsewhere classified                                  Frequently used for exacerbation of COPD
  J96.0         Acute respiratory failure                                                      Frequently used for exacerbation of COPD
  J96.9         Respiratory failure, unspecified                                               Frequently used for exacerbation of COPD
  J46           Status asthmaticus                                                             Frequently used for exacerbation of COPD
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###### 

Baseline characteristics of the study participants divided in two subgroups ICM-yes and ICM-no.

                  ICM-yes                 ICM-no
  --------------- ----------------------- -----------------------
  Age (average)   72                      71
  Age (median)    71                      70
  Sex             Male (n= 31; 70.45%)    Male (n=82; 62.60%)
                  Female (n=13; 29.54%)   Female (n=49; 37.40%)

###### 

Stages of cost analysis with types of costs included.

  Stage of analysis   Type of costs               Type of procedures included
  ------------------- --------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  I                   General                     All medical procedures realized for patients
  II                  COPD related                Medical procedures realized due to COPD and other diseases of the respiratory system (the list of DRG codes of diseases and conditions requiring medical procedures included in stage II is available in [Supplementary Table 1](#s1-medscimonit-23-2850){ref-type="supplementary-material"})
  III                 Exacerbation related (ER)   Medical procedures realized due to exacerbations of COPD (the list of DRG codes of diseases and conditions requiring medical procedures included in stage III is available in [Supplementary Table 2](#s2-medscimonit-23-2850){ref-type="supplementary-material"}).

###### 

Direct medical costs of standard care in patients with COPD divided into: general costs, system related costs of COPD and other diseases of the respiratory system and related costs of exacerbations of COPD (in PLN).

  Type of cost                N     Mean                    Median                  Dominant   Dominant representation   Minimal value   Maximal value
  --------------------------- ----- ----------------------- ----------------------- ---------- ------------------------- --------------- --------------------------
  General costs in intro−6m   154   3870.26 (≈886.78 EUR)   1087.18 (≈249.10 EUR)   0          18                        0               45456.91 (≈10415.38 EUR)
  COPD costs in intro−6m      152   1599.03 (≈366.38 EUR)   91.35 (≈20.93 EUR)      0          46                        0               20071.54 (≈4598.92 EUR)
  ER costs in intro−6m        65    1571.28 (≈360.02 EUR)   0                       0          34                        0               20010.64 (≈4584.97 EUR)

###### 

Direct medical costs of three types of before and after, including patients in ICM (group ICM-yes) (in PLN and EUR) with results of Wilcoxon's Matched-Pairs Signed-Rank test.

  Period                                            N    Mean                    Median                  Dominant   Dominant representation   Min. value          Max. value                p value
  ------------------------------------------------- ---- ----------------------- ----------------------- ---------- ------------------------- ------------------- ------------------------- ----------
  General costs                                                                                                                                                                             
  Intro−6m                                          41   5627.29 (≈1289.36EUR)   3708.72 (»849.77 EUR)   0          1                         30.45 (≈6.98 EUR)   29671.15 (≈6798.45 EUR)   0.079114
  Intro+6m                                          41   3576.79 (≈819.54 EUR)   2388.4 (»547.25 EUR)    0          2                         0                   16765.1 (≈3841.33 EUR)    
  COPD and other respiratory system disease costs                                                                                                                                           
  Intro−6m                                          41   3191.43 (≈731.24EUR)    2168.1 (»496.77 EUR)    0          3                         0                   20071.54 (≈4598.92 EUR)   0.012492
  Intro+6m                                          41   1741.31 (≈398.98 EUR)   157.5 (»36.09 EUR)      0          6                         0                   9314.65 (≈2134.23 EUR)    
  Exacerbation costs                                                                                                                                                                        
  Intro−6m                                          26   2443.61 (≈559.9EUR)     1872 (»428.92EUR)       0          7                         0                   20010.64 (≈4584.97EUR)    0.017023
  Intro+6m                                          26   735.17 (≈168.45EUR)     0                       0          18                        0                   5539.5 (≈1269.25EUR)      

###### 

Comparison of studies dealing with integrated care.

  Author (year)                                              IC programme country       Types of intervention used                                                                                                                                                                        Main assumptions of ICM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  ---------------------------------------------------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  **Base for comparison -- main assumption of ICM Poland**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Bandurska et al. (2016)                                    Poland                     Cooperation between specialist and general careCoordination of treatmentSupervision of patient's complianceHome careEducation and promotion of self-managementSupport of multidisciplinary team   Study construction-- Pre-post study-- 6 months follow up after introducing IC-- Multivariate cost analysisIC model construction-- Home based support-- Supervision of compliance-- Multidisciplinary team-- Education for patients and families-- ICM available for patients in advanced COPD.Results obtained-- Reduction in costs-- Reduction in prevalence of hospitalizations and ER visits-- More services realized by GPs and ambulatory clinics                                                                                                                                                                                 
  Comparison with IC studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Author (year)**                                          **IC programme country**   **Types of intervention used**                                                                                                                                                                    **Similarities (ICM)In study design.In IC model construction.In results obtained**                                                                                                                                                                                                                                                                                                                                                                       **Differences (ICM)In study design.In IC model construction.In results obtained**                                                                                             **Positive impact of IC**
  Boven et al. (2014)                                        Belgium                    Supervision of patient's compliance                                                                                                                                                               -- Multivariate cost analysis-- Analysis of changes in number of hospitalizations-- Supervision of patient's compliance and inhaling technique-- Savings after introducing IC-- Reduction in number of hospitalizations                                                                                                                                                                                                                                  -- 12 months follow-up-- Pharmacy based intervention-- Focused on compliance to pharmaceutical treatment-- Other type of pharmacoeconomic analysis used -- QALY assessment    -- Savings of 227 EUR/year/patient-- Prevention of 0.07 hospitalization/patient
  Steuten et al.                                             Netherlands                Support of multidisciplinary team.Education and promotion of self-management.Coordination of treatmentSupervision of patient's compliance                                                         -- Pre-post test design-- 3 months follow up-- Multidisciplinary team cooperation-- Education and promotion of self-management-- Reduction in number of hospitalizations                                                                                                                                                                                                                                                                                 -- Cost analysis of losses of productivity;-- 12 months follow-up-- Lack of home care-- No significant savings found after introducing IC                                     -- Reduction in hospitalization by 50%-- Reduction in non-routine consultations by 25%
  Hermiz et al. (2002)                                       Australia                  Supervision of patient's complianceHome careEducation and promotion of self-management                                                                                                            -- Analysis of number of hospitalizations-- Home and telephone visits-- None                                                                                                                                                                                                                                                                                                                                                                             -- Analysis of effects without costs assessment-- 1 month follow-up-- No multidisciplinary team-- No coordination of treatment-- No reduction in number of hospitalizations   -- Improved knowledge about disease among patients
  Casas et al. (2006)                                        Belgium, Spain             Coordination of treatment (individual treatment plan)Multidisciplinary teamWeb-based centreEducation and promotion of self-management                                                             -- Analysis of number of hospitalizations-- Engagement of GPs-- Coordination of treatment-- Education of patients-- Reduction of hospitalizations                                                                                                                                                                                                                                                                                                        -- No cost analysis-- 12 months follow up after IC-- Web-based centre-- Lack of home care-- Decrease in number of GPs visits                                                  -- Lower number of re-hospitalizations -- 1.5±2.6 versus 2.1±3.1.
  Titova et al. (2015)                                       Norway                     Coordination of treatment (individual treatment plan)Multidisciplinary teamCall centreEducation and promotion of self-management                                                                  -- IC available only for patients with advanced COPD (stage III--IV GOLD)-- Analysis of hospital utilization-- Multidisciplinary team-- Coordination of treatment-- Education of patients-- Reduction in hospital utilization                                                                                                                                                                                                                            -- 2 years follow-up-- No cost analysis-- E-learning programme for patients-- No cost specific data to compare                                                                -- Reduction in hospital utilization
  Boland et al. (2015)                                       Netherlands                Coordination of treatment (individual treatment plan)Multidisciplinary teamICT programme to support clinical decision-makingClusters of primary care teams                                        -- Analysis of impact of IC on costs-- Coordination of treatment (individual treatment plan)-- Multidisciplinary team-- None                                                                                                                                                                                                                                                                                                                             -- 2 years follow-up-- Clusters of primary care teams-- ICT programme to support clinical decision-making-- No reduction of costs in IC group                                 -- None
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